HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate regulatory moratorium "legislative review" approach passes unanimously March 29.

This article was originally published in The Rose Sheet

Executive Summary

SENATE 45-DAY "LEGISLATIVE REVIEW" REGULATORY MORATORIUM PASSES unanimously by recorded vote March 29. The Senate version of regulatory moratorium legislation (S 219) adopts the bipartisan approach introduced by Sens. Don Nickles (R-OK) and Harry Reid (D-NV). Unlike the House bill (HR 450), which would forbid agencies to promulgate any significant rule (with some exceptions) until Dec. 31 or until regulatory reform legislation is enacted, S 219 would delay adoption of any significant regulation by 45 days to give Congress the opportunity to review and potentially reject the reg.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel